Source author record

Norbert Benda

Norbert Benda appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Applications Quantitative Methods

Catalog footprint

What is connected

3works

2topics

4close collaborators

Actions

Connect this record

Open graph Browse works

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

preprint2020arXiv

Efficient adaptive designs for clinical trials of interventions for COVID-19

The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the natural history of the disease and the number and characteristics of patients affected, and the emergence of new potential therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently strong evidence has been observed to answer the research question, without compromising the trial's scientific validity or integrity. In this paper we describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting. Our discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.

preprint2020arXiv

Subgroup identification in individual patient data meta-analysis using model-based recursive partitioning

Model-based recursive partitioning (MOB) can be used to identify subgroups with differing treatment effects. The detection rate of treatment-by-covariate interactions and the accuracy of identified subgroups using MOB depend strongly on the sample size. Using data from multiple randomized controlled clinical trials can overcome the problem of too small samples. However, naively pooling data from multiple trials may result in the identification of spurious subgroups as differences in study design, subject selection and other sources of between-trial heterogeneity are ignored. In order to account for between-trial heterogeneity in individual participant data (IPD) meta-analysis random-effect models are frequently used. Commonly, heterogeneity in the treatment effect is modelled using random effects whereas heterogeneity in the baseline risks is modelled by either fixed effects or random effects. In this article, we propose metaMOB, a procedure using the generalized mixed-effects model tree (GLMM tree) algorithm for subgroup identification in IPD meta-analysis. Although the application of metaMOB is potentially wider, e.g. randomized experiments with participants in social sciences or preclinical experiments in life sciences, we focus on randomized controlled clinical trials. In a simulation study, metaMOB outperformed GLMM trees assuming a random intercept only and model-based recursive partitioning (MOB), whose algorithm is the basis for GLMM trees, with respect to the false discovery rates, accuracy of identified subgroups and accuracy of estimated treatment effect. The most robust and therefore most promising method is metaMOB with fixed effects for modelling the between-trial heterogeneity in the baseline risks.

preprint2016arXiv

Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions

BACKGROUND: Randomized controlled trials (RCTs) are the gold standard design of clinical research to assess interventions. However, RCTs cannot always be applied for practical or ethical reasons. To investigate the current practices in rare diseases, we review evaluations of therapeutic interventions in paediatric multiple sclerosis (MS) and Creutzfeldt-Jakob disease (CJD). In particular, we shed light on the endpoints used, the study designs implemented and the statistical methodologies applied. METHODS: We conducted literature searches to identify relevant primary studies. Data on study design, objectives, endpoints, patient characteristics, randomization and masking, type of intervention, control, withdrawals and statistical methodology were extracted from the selected studies. The risk of bias and the quality of the studies were assessed. RESULTS: Twelve (seven) primary studies on paediatric MS (CJD) were included in the qualitative synthesis. No double-blind, randomized placebo-controlled trial for evaluating interventions in paediatric MS has been published yet. Evidence from one open-label RCT is available. The observational studies are before-after studies or controlled studies. Three of the seven selected studies on CJD are RCTs, of which two received the maximum mark on the Oxford Quality Scale. Four trials are controlled observational studies. CONCLUSIONS: Evidence from double-blind RCTs on the efficacy of treatments appears to be variable between rare diseases. With regard to paediatric conditions it remains to be seen what impact regulators will have through e.g., paediatric investigation plans. Overall, there is space for improvement by using innovative trial designs and data analysis techniques.